Peptide Research in Lupus (SLE)

Autoimmune Peptide Therapies

70% antibody reduction

In a phase II trial of the P140 peptide, 7 of 10 patients at the lower dose showed at least a 20% decrease in anti-dsDNA antibodies, the hallmark of lupus.

Muller et al., Arthritis & Rheumatism, 2008

Muller et al., Arthritis & Rheumatism, 2008

View as image

Systemic lupus erythematosus (SLE) is an autoimmune disease where the immune system attacks the body's own tissues, producing antibodies against DNA, RNA-binding proteins, and other nuclear components. Current treatments rely on broad immunosuppression (corticosteroids, hydroxychloroquine, mycophenolate, belimumab), which controls symptoms but increases infection risk and has cumulative toxicity. Peptide-based approaches aim to selectively correct the specific immune dysregulation that drives lupus, rather than suppressing the entire immune system. Several peptide strategies have reached clinical trials, though none have yet achieved approval. For context on how peptide-based tolerance induction works across autoimmune diseases, see our pillar article on peptide therapies for autoimmune disease.

Why Lupus Is Uniquely Suited to Peptide Immunotherapy

Lupus is driven by specific, identifiable autoantigen targets. The immune system produces antibodies against double-stranded DNA (anti-dsDNA), ribonucleoprotein complexes (anti-Smith, anti-RNP), and other nuclear components. These autoantibodies form immune complexes that deposit in kidneys, joints, skin, and blood vessels, causing inflammation and tissue damage.

Because the autoantigens are known, peptide immunotherapy can be designed to specifically tolerize the immune cells that recognize them. This is the same approach used in type 1 diabetes peptide immunotherapy, where proinsulin peptides retrain T cells toward tolerance. In lupus, the challenge is more complex because multiple autoantigens are targeted simultaneously, and the autoimmune response involves both T cells and B cells in intricate feedback loops.

Schall et al. (2012) reviewed the state of peptide-based approaches to lupus treatment, identifying four major strategies.^[1] These include tolerogenic peptides that induce T-cell tolerance, B-cell tolerizing agents that eliminate anti-dsDNA B cells, peptides derived from anti-DNA antibody complementarity-determining regions (CDRs) that modulate pathogenic immune responses, and neuropeptide-based approaches that shift the inflammatory milieu.

P140: The Most Clinically Advanced Lupus Peptide

The peptide P140 (also called IPP-201101 or Lupuzor) is a 21-amino-acid fragment of the U1-70K spliceosomal protein, phosphorylated at serine 140. This specific post-translational modification is critical: unmodified versions of the same peptide sequence do not have the same tolerogenic effect.

Muller et al. (2008) published results from an open-label, dose-escalation phase II trial in SLE patients.^[2] Twenty patients with moderately active SLE received three subcutaneous injections of P140 at two-week intervals. Key results:

• At the lower dose (200 mcg), 7 of 10 patients showed at least a 20% decrease in IgG anti-dsDNA antibody levels
• Physician's global assessment scores decreased after treatment
• SLE Disease Activity Index (SLEDAI) scores were reduced
• The peptide was well tolerated with no serious adverse events

The mechanism of P140 involves inducing tolerogenic dendritic cells and regulatory T cells. P140 is taken up by antigen-presenting cells and processed through a pathway that leads to immune tolerance rather than activation. The phosphorylation at Ser140 appears to target the peptide to specific intracellular compartments involved in MHC class II loading, channeling the immune response toward tolerance.

P140 subsequently entered a randomized, placebo-controlled phase III trial (NCT02504645), though results from this later trial did not replicate the phase II success to the same degree, highlighting the challenge of translating small open-label studies to larger controlled settings.

LL-37: When an Antimicrobial Peptide Becomes an Autoantigen

One of the most unexpected findings in lupus research involves LL-37, the only human cathelicidin antimicrobial peptide. In psoriasis, LL-37 was already known to drive autoimmunity by binding self-DNA and stimulating plasmacytoid dendritic cells to produce type I interferon. Lande et al. (2020) showed that LL-37 plays an analogous dual role in SLE.^[3]

Their study found that LL-37-specific T cells exist in SLE patients and actively help B cells produce the anti-DNA autoantibodies that drive lupus pathology. Both native and citrullinated forms of LL-37 serve as autoantigens, with citrullinated LL-37 being particularly effective at stimulating pathogenic T-cell responses.

This has two implications for peptide research in lupus. First, it reveals an unexpected peptide target: therapeutic strategies that reduce LL-37 autoimmunity could potentially dampen the anti-DNA response. Second, it demonstrates how the body's own antimicrobial peptides can become drivers of autoimmune disease, an emerging theme that connects innate immunity to autoimmune pathology in ways previously unrecognized.

The concept of altered peptide ligands could be applied here: modified versions of LL-37 might be designed to tolerize LL-37-reactive T cells rather than activate them, breaking the autoimmune cycle at its source.

This finding also raises questions about therapeutic peptides that contain LL-37 or LL-37-like sequences. Any peptide therapy used in lupus patients would need to be screened for potential cross-reactivity with LL-37-specific immune responses, since accidentally boosting LL-37 autoimmunity could worsen disease rather than improve it. The broader principle is that antimicrobial peptides, normally protective against infection, can become pathogenic drivers when the immune system loses self-tolerance.

VIP: A Neuropeptide Approach to Lupus Nephritis

Lupus nephritis (kidney inflammation) is the most dangerous manifestation of SLE, causing kidney failure in 10-30% of affected patients. Vasoactive intestinal peptide has been explored as a therapeutic because of its potent immunomodulatory properties.

Fu et al. (2019) tested VIP treatment in a pristane-induced lupus mouse model.^[4] The pristane model recapitulates many features of human lupus, including autoantibody production and nephritis. VIP treatment:

• Restored the balance between Th17 cells (pro-inflammatory) and regulatory T cells (anti-inflammatory), which is disrupted in lupus
• Reduced renal inflammation and tissue damage
• Decreased levels of pro-inflammatory cytokines in the kidney

The Th17/Treg imbalance is a core driver of lupus nephritis. Th17 cells promote inflammation and tissue destruction, while Tregs suppress autoimmune responses. In lupus, this balance shifts strongly toward Th17 dominance. VIP shifts it back by promoting Treg differentiation and suppressing Th17 polarization, mechanisms consistent with its broader role in generating tolerogenic dendritic cells.

GLP-1 Agonists: An Unexpected Metabolic Connection

The intersection of metabolic peptide drugs with lupus emerged from two observations: SLE patients have massively elevated cardiovascular risk (10-50x higher myocardial infarction rates in young women), and GLP-1 agonists have cardiovascular protective effects beyond glucose control.

Carlucci et al. (2025) conducted a retrospective evaluation of GLP-1 receptor agonists in SLE patients.^[5] Their analysis examined whether these drugs, prescribed primarily for diabetes or obesity, had effects on lupus disease activity and cardiovascular outcomes. The study found cardiometabolic benefits without triggering lupus flares, an important safety signal given that a recent case report had raised concerns about GLP-1 agonist-induced lupus.

Jiang et al. (2026) provided mechanistic support for GLP-1 agonists in lupus, showing that liraglutide prevented lupus-associated diffuse alveolar hemorrhage (DAH) in a mouse model.^[6] DAH is a life-threatening complication of SLE. Liraglutide reduced lymphocyte infiltration into the lungs and decreased the inflammatory signaling that drives alveolar damage. This anti-inflammatory mechanism is distinct from liraglutide's metabolic effects and consistent with the GLP-1 receptor's expression on immune cells.

The potential of GLP-1 agonists in lupus represents a different paradigm from traditional peptide immunotherapy: rather than targeting specific autoantigens, these metabolic peptides may broadly dampen the inflammatory environment that sustains autoimmunity.

Other Peptide Approaches That Have Been Tested

Several other peptide strategies have been explored in lupus clinical trials:

LJP-394 (Abetimus sodium) was a tetrameric oligonucleotide conjugate designed to tolerize anti-dsDNA B cells. It successfully reduced anti-dsDNA antibody levels in 14 clinical trials but failed to meet primary endpoints in two pivotal trials measuring time to renal flare. The disconnect between antibody reduction and clinical outcomes highlighted that anti-dsDNA antibodies alone do not fully explain lupus nephritis progression.

hCDR1 (Edratide) is a peptide derived from the complementarity-determining region of a human anti-DNA antibody. It was designed to down-regulate the pathogenic anti-DNA response from the antibody side rather than the antigen side. Clinical studies showed that hCDR1 reduced disease activity scores (SLEDAI-2K and BILAG) and down-regulated pathogenic cytokines including IFN-alpha, IL-1beta, and TNF-alpha. However, it did not advance to late-stage clinical trials.

Nucleosomal histone peptide epitopes have been investigated as tolerogenic agents that target the anti-nucleosome response in lupus. Nucleosomes (DNA wrapped around histone proteins) are major autoantigens in SLE, and histone-derived peptides can selectively down-regulate the pathogenic autoimmune response when administered in tolerogenic conditions. Researchers have identified specific histone peptide epitopes (H2B 10-33, H4 16-39, H4 71-94) that are recognized by lupus T cells and can be used to induce antigen-specific tolerance when delivered in non-inflammatory contexts. The approach has shown efficacy in murine lupus models, reducing nephritis severity and prolonging survival, but human clinical testing remains limited.

These negative and mixed results across multiple peptide candidates illustrate a recurring challenge: the gap between reducing a biomarker (antibody levels, T-cell reactivity) and changing clinical outcomes (kidney function, flare rate, survival). This gap may be unique to lupus, where the relationship between any single immune parameter and organ damage is indirect and mediated by dozens of intermediate steps.

Where the Field Stands

Peptide immunotherapy for lupus has demonstrated proof of concept (P140 phase II results, VIP in animal models, hCDR1 clinical data) but has not yet produced a clinically approved therapeutic. The challenges are substantial:

• Lupus targets multiple autoantigens simultaneously, making single-peptide approaches insufficient
• Disease heterogeneity means different patients may respond to different peptide targets
• Clinical trial design in lupus is difficult because disease activity fluctuates unpredictably
• The gap between antibody reduction and clinical outcomes (as seen with LJP-394) suggests that simple immune tolerance induction may not be enough

The most promising near-term development may not be a lupus-specific peptide at all. GLP-1 agonists are already prescribed to millions of patients for diabetes and obesity, meaning their safety profile is well-established. If the cardiovascular and anti-inflammatory benefits observed in SLE patients are confirmed in prospective studies, these drugs could be repurposed for lupus cardiometabolic risk reduction without requiring a new approval pathway.

The emerging GLP-1 agonist data adds a new dimension: broadly anti-inflammatory peptide drugs may complement antigen-specific tolerogenic approaches. Combination strategies using tolerogenic peptides plus anti-inflammatory metabolic peptides represent an untested but conceptually appealing approach to lupus management. For a broader perspective on this field, see our article on peptide immunotherapy for multiple sclerosis, which faces many of the same translational challenges.

The Bottom Line

Peptide research in lupus spans tolerogenic peptides (P140, hCDR1), B-cell tolerizing agents (LJP-394), neuropeptide therapy (VIP for nephritis), antimicrobial peptide autoimmunity (LL-37 as autoantigen), and metabolic peptides (GLP-1 agonists). The P140 spliceosomal peptide has the strongest clinical data, reducing anti-dsDNA antibodies and disease activity in a phase II trial. The discovery that LL-37 drives autoantibody production opens new therapeutic targets. GLP-1 agonists provide anti-inflammatory benefits without triggering lupus flares, suggesting a complementary role to antigen-specific approaches.

Frequently Asked Questions

Can peptides treat lupus?

Several peptide-based therapies for lupus have reached clinical trials. The P140 spliceosomal peptide (IPP-201101/Lupuzor) reduced anti-dsDNA antibodies in 7 of 10 patients and decreased disease activity in a phase II trial (Muller et al., 2008). However, no peptide therapy is currently approved for SLE. The challenge is translating promising early results into consistent efficacy in larger controlled trials.

What is the P140 peptide for lupus?

P140 is a 21-amino-acid fragment of the U1-70K spliceosomal protein with a phosphorylation at serine 140. It works by inducing tolerogenic dendritic cells and regulatory T cells that suppress the autoimmune response driving lupus. In a phase II trial of 20 patients, it reduced anti-dsDNA antibodies and SLEDAI scores with good tolerability. The phosphorylation is critical for its tolerogenic effect.

How does LL-37 contribute to lupus?

The antimicrobial peptide LL-37 acts as an autoantigen in SLE. Lande et al. (2020) found that LL-37-specific T cells help B cells produce the anti-DNA autoantibodies characteristic of lupus. Both native and citrullinated forms of LL-37 drive this pathogenic response. LL-37 also stimulates plasmacytoid dendritic cells to produce type I interferon, a key cytokine in lupus pathogenesis.

Can VIP treat lupus nephritis?

In animal models, VIP (vasoactive intestinal peptide) ameliorated lupus nephritis by restoring the Th17/Treg balance. Fu et al. (2019) showed that VIP treatment reduced renal inflammation and tissue damage in pristane-induced lupus mice. VIP promotes regulatory T cell differentiation while suppressing pro-inflammatory Th17 cells. Human clinical trials of VIP for lupus nephritis have not been conducted.

Are GLP-1 drugs safe for lupus patients?

A retrospective evaluation by Carlucci et al. (2025) found that GLP-1 receptor agonists in SLE patients provided cardiometabolic benefits without triggering lupus flares. This is important because SLE patients have elevated cardiovascular risk. Animal studies also show that liraglutide can reduce lupus-associated lung damage (Jiang et al., 2026). However, one case report of drug-induced lupus from a GLP-1 agonist has been published, so monitoring is appropriate.

Why did LJP-394 fail in lupus trials?

LJP-394 (abetimus sodium) successfully reduced anti-dsDNA antibody levels across 14 clinical trials but failed to extend time to renal flare in two pivotal studies. This revealed that reducing a single autoantibody species is insufficient to prevent organ damage in lupus, likely because multiple pathogenic mechanisms (immune complex deposition, complement activation, T-cell mediated inflammation) contribute to nephritis independently of anti-dsDNA levels.